Stay updated on Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial

Sign up to get notified when there's something new on the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    Results posting details were added: Results First Submitted (2026-01-05), Results First Posted with QC Comments (2026-01-22), Results First Posted (2026-02-10), and associated PDFs such as the Study Protocol and Informed Consent Form.
    Difference
    3%
    Check dated 2026-02-11T16:22:28.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A site-wide notice about the lapse in government funding and NIH operations was added, and the page revision updated from v3.4.0 to v3.4.1.
    Difference
    0.5%
    Check dated 2026-02-04T10:44:28.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Introduces a glossary toggle and updates metadata labels (Last Update Submitted that Met QC Criteria and Last Update Posted) along with the revision to v3.4.0.
    Difference
    0.3%
    Check dated 2026-01-28T06:24:32.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Revision label on the page updated from `Revision: v3.3.3` to `Revision: v3.3.4`.
    Difference
    0.1%
    Check dated 2026-01-14T02:29:03.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The study page now shows 'Results Submitted' in place of 'No Results Posted', indicating that results have been submitted.
    Difference
    0.1%
    Check dated 2026-01-07T01:47:46.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    Added a Locations section with Texas as a study site and updated the revision to v3.3.3; the old Texas Locations label and the HHS Vulnerability Disclosure link were removed.
    Difference
    0.2%
    Check dated 2025-12-23T21:33:10.000Z thumbnail image

Stay in the know with updates to Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page.